Skip to main content
padlock icon - secure page this page is secure

2,3,5,4'tetrahydroxystilbene2OβDglucoside attenuates methionine and cholinedeficient dietinduced nonalcoholic fatty liver disease

Buy Article:

$42.00 + tax (Refund Policy)

Previous studies have suggested that 2,3,5,4'tetrahydroxystilbene2OβDglucoside (TSG) prevents progression of nonalcoholic fatty liver disease (NAFLD) induced by highfat diet. The present study aimed to evaluate whether TSG could reverse NAFLD induced by a methionine and cholinedeficient (MCD) diet and identify the possible mechanism of action. C57BL6/J mice were fed a MCD diet and were treated with TSG, fenofibrate, and resveratrol for 9 weeks. Regulatory effects of several cytokines and enzymes, including Nodlike receptor protein 3, apoptosisassociated specklike protein containing a C-terminal caspase recruitment domain (ASC), caspase1, interleukin (IL)18, IL1β, and gut microbiota balance were investigated. TSG significantly reduced NAFLD biochemical indexes, including total cholesterol, triglyceride, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, aspartate aminotransferase and free fatty acid. Middle dosage (TSG.M, 35 mg/kg) of TSG reduced the expression of ASC and caspase1. Furthermore, TSG displayed gut microbiota regulatory effects on MCDinduced NAFLD mice. The results of the present study suggested that TSG prevented the occurrence and development of MCD dietinduced NAFLD. The data further indicated that TSG may serve as a promising lead compound that may aid with intervention in NAFLD therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: College of Pharmaceutical Science, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, P.R. China

Publication date: August 1, 2018

More about this publication?
  • Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.

    All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more